Publications by authors named "May-Britt Five"
Article Synopsis
- Cystoscopy is the standard method for monitoring non-muscle invasive bladder cancer (NMIBC), but it is invasive and not always accurate.
- This study explored using urine tumor DNA (utDNA) analysis as a less invasive alternative, following 47 patients over two years and employing BladMetrix DNA methylation tests during cystoscopy appointments.
- The results showed that utDNA detected 91% of recurrences, allowed for a 55% reduction in cystoscopies needed, and identified 48% of recurrences earlier than cystoscopy, indicating that utDNA could help personalize and improve surveillance for bladder cancer.
Background: Cystoscopy is the gold standard for bladder cancer detection, but is costly, invasive and has imperfect diagnostic accuracy. We aimed to identify novel and accurate DNA methylation biomarkers for non-invasive detection of bladder cancer in urine, with the potential to reduce the number of cystoscopies among hematuria patients.
Results: Biomarker candidates (n = 32) were identified from methylome sequencing of urological cancer cell lines (n = 16) and subjected to targeted methylation analysis in tissue samples (n = 60).
Background: Despite the efforts to describe the molecular landscape of esophageal adenocarcinoma (EAC) and its precursor lesion Barrett's esophagus (BE), discrepant findings are reported. Here, we investigated the prevalence of selected genetic (TP53 mutations and microsatellite instability (MSI) status) and epigenetic (DNA promoter hypermethylation of APC, CDKN2A, MGMT, TIMP3 and MLH1) modifications in a series of 19 non-dysplastic BE and 145 EAC samples. Additional biopsies from adjacent normal tissue were also evaluated.
View Article and Find Full Text PDF